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ABSTRACT
Background: Despite increasing incidence of hepatocellular carcinoma (HCC) among 
HIV-infected patients, it remains unclear if HIV-related factors contribute to 
development of HCC. We examined if higher or prolonged HIV viremia and lower CD4+
cell percentage were associated with HCC.
Methods: We conducted a cohort study of HIV-infected individuals who had HIV RNA,
CD4+, and CD8+ cell counts and percentages assessed in the Veterans Aging Cohort 
Study (1999-2015). HCC was ascertained using Veterans Health Administration 
cancer registries and electronic records. Cox regression was used to determine 
hazard ratios (HR [95% confidence interval]) of HCC associated with higher current 
HIV RNA, longer duration of detectable HIV viremia (≥500 copies/mL), and current 
CD4+ cell percentage <14%, adjusting for traditional HCC risk factors. Analyses were 
stratified by previously validated diagnoses of cirrhosis prior to start of follow-up.
Results: Among 35,659 HIV-infected patients, 302 (0.8%) developed HCC over 
281,441 person-years (incidence rate, 107.3/100,000 person-years). Among 
patients without baseline cirrhosis, higher HIV RNA (1.25 [1.12-1.40] per 1.0 log10 
copies/mL) and ≥12 months of detectable HIV (1.47 [1.02-2.11]) were 
independently associated with higher risk of HCC. CD4+ percentage <14% was not 
associated with HCC in any model. Hepatitis B and C coinfection were each 
significant predictors of HCC regardless of baseline cirrhosis status.
Conclusion: Among HIV-infected patients without baseline cirrhosis, higher HIV 
RNA and longer duration of HIV viremia increased risk of HCC, independent of 
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traditional HCC risk factors. This is the strongest evidence to date that HIV viremia 
contributes to risk of HCC in this group.
5
64
65
66
INTRODUCTION
Hepatocellular carcinoma (HCC) is a growing cause of cancer death among 
people living with HIV infection.1 Driven largely by hepatitis C virus (HCV) coinfection, 
hepatitis B virus (HBV) coinfection, and alcoholic liver disease, the incidence of HCC 
among HIV-infected persons in North America has risen more than 4-fold from 1995-
2009.2 Moreover, HIV-infected individuals have a 4-fold higher risk of HCC than 
uninfected persons.3
Despite the rising incidence of HCC among HIV-infected individuals, the 
determinants of this malignancy remain largely unknown in this group.4 Three prior 
studies found no association between HIV suppression and risk of HCC,5-7 but these 
studies did not evaluate the effects of longer durations or higher levels of HIV viremia, 
nor did they account for cirrhosis. Moreover, previous studies among predominantly 
HIV/HCV-coinfected patients reported that lower absolute CD4+ cell counts increased 
the risk of HCC.6,8-12 However, absolute CD4+ cell count may decrease during cirrhosis 
due to portal hypertension-induced splenic sequestration.13 Thus, studies evaluating 
associations between absolute CD4+ cell count and HCC risk cannot determine 
whether observed associations are driven by HIV-related immunosuppression or 
progression of liver disease. Consequently, it remains unclear if higher HIV RNA levels,
longer duration of detectable HIV, and HIV-related immunosuppression contribute to 
development of HCC independent of traditional determinants. Identifying such factors 
could help define the mechanisms for the high rate of HCC among HIV-infected 
persons. 
Cirrhosis, which represents the late stage of progressive hepatic fibrosis due 
to chronic liver disease, is an important step in the causal pathway towards HCC 
(Figure 1).14 Cirrhosis promotes HCC through telomere dysfunction and alterations 
6
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
of the liver milieu (e.g., increased production of toxic hepatic metabolites, 
cytokines, growth factors, and products of oxidative stress).15 Since cirrhosis 
increases the risk of HCC substantially, studies evaluating the factors associated 
with HCC must account for baseline cirrhosis status.
We evaluated HIV-related and traditional risk factors for HCC among HIV-
infected patients. We hypothesized that higher HIV RNA levels, longer duration of 
HIV viremia, and lower CD4+ cell percentage, which is not affected by liver disease 
progression,13 were significant determinants of HCC. We also examined the risk of 
HCC with traditional risk factors in the general population, including older age, black
race, overweight/obesity, diabetes mellitus, alcohol dependence/abuse, tobacco 
use, and HBV and HCV coinfection.16 To account for the role of cirrhosis in the 
development of HCC and the possibility that risk factors for HCC might vary by 
presence of cirrhosis, we stratified our analysis by baseline cirrhosis status.
METHODS
Study Design and Data Source
We conducted a retrospective cohort study among HIV-infected individuals in 
the Veterans Aging Cohort Study (VACS) between October 1, 1999 and September 30,
2015.17 The VACS consists of electronic medical record data from HIV-infected 
patients receiving care at Veterans Health Administration (VA) facilities across the 
United States (US). Data include demographics, hospital and outpatient diagnoses 
(recorded using International Classification of Diseases, Ninth Revision [ICD-9] codes),
procedures, laboratory results, and dispensed medications. Death date was 
determined from the VA Vital Status File. The study was approved by the Institutional 
Review Boards of the University of Pennsylvania, Corporal Michael Crescenz VA 
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Medical Center in Philadelphia, VA Connecticut Healthcare System, and Yale 
University.
Study Patients
HIV-infected patients were included if they had: 1) HIV RNA, CD4+, and CD8+ 
count/percentage simultaneously assessed (which occurs routinely as part of HIV care
in the VA system) between October 1, 1999 and September 30, 2015, and 2) at least 
180 days of observation after determination of these laboratory results. We defined 
the start of follow-up as 180 days after the date that HIV RNA, CD4+, and CD8+ 
results were assessed. The 180 days prior to start of follow-up represented the 
baseline period, during which baseline comorbidities and laboratory results were 
collected. Patients were excluded if they had HCC diagnosed prior to start of follow-
up. Follow-up continued until HCC, death, or last VA visit before September 30, 2015.
Main Study Outcomes
The primary outcome was incident HCC diagnosis. HCC diagnoses were 
determined from the VA national cancer registry by topography code C22.0 (liver) and 
morphology codes 8170-8180 (HCC) from the International Classification of Diseases 
for Oncology, Third Edition (ICD-O-3),18 consistent with Surveillance, Epidemiology, and 
End Results coding algorithms.19 The VA cancer registry records cancers diagnosed 
and/or treated within the VA.7 ICD-O-3 codes validly identify cancer diagnoses, 
including HCC.20 To account for lags in reporting diagnoses in the cancer registry and 
minimize the likelihood of missing HCC events, we supplemented HCC case finding with
ICD-9 diagnoses for HCC (155.0, 155.1, and 155.2) recorded in the VA electronic 
medical record. Prior research has shown that use of both VA cancer registry records 
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and ICD-9 diagnoses have 90% sensitivity for incident cancer diagnosis when 
compared to chart review; however, positive predictive value varied (96% for VA 
cancer registry; 63% for ICD-9 diagnosis).20,21 Consequently, HCC diagnoses from the 
registry and claims were confirmed by medical record review by trained adjudicators. 
For all confirmed HCC cases, we determined the presence of cirrhosis by review of 
medical records within one year prior to HCC diagnosis. Details on cirrhosis 
adjudication appear in Appendix 1.
Data Collection
Baseline data included: age; sex; race/ethnicity; body mass index (BMI); 
diabetes (defined by random glucose 200 mg/dL, hemoglobin A1c ≥6.5%, or anti-
diabetic drug use22); alcohol dependence/abuse; injection/non-injection drug use; 
tobacco use (ever); HBV coinfection (ever positive HBV surface antigen); HCV 
coinfection (ever detectable HCV RNA or genotype); cirrhosis; HIV RNA; absolute 
CD4+ and CD8+ counts and percentages; and antiretroviral therapy (ART) use. 
Cirrhosis was defined by a hospital discharge diagnosis or outpatient diagnosis for 
cirrhosis or hepatic decompensation (Appendix 2). Prior studies validated this 
determination within the VA system, with ≥90% of these diagnoses confirmed by 
medical records.23,24 Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and platelet count were collected from dates closest, but within 360 days 
prior, to start of follow-up. FIB-4, a non-invasive measure of hepatic fibrosis, was 
calculated by: (age [years] x AST [U/L])/(platelet count [109/L]) x (ALT [U/L])1/2).25
Time-varying variables were assessed on a monthly basis and included HIV 
RNA, CD4+ and CD8+ counts/percentages, and diabetes. When multiple results of the 
same test were measured within a month, in order to be most conservative, we used 
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the highest HIV RNA and CD8+ result, and lowest CD4+ result. When a test was not 
updated during a month, we carried forward the value from the previous month until 
the next available result. HIV RNA, CD4+, and CD8+ results were updated at the 
beginning of each 30-day interval from baseline but were lagged by 180 days 
(approximate mean doubling time of HCC tumors <5 centimeters in length26) to 
reduce the possibility that the presence of HCC influenced these variables (i.e., 
reverse causality).
Statistical Analysis
We determined unadjusted incidence rates (IR) of HCC (events/100,000 
person-years), overall and by HBV and HCV status. We used multivariable Cox 
regression to determine adjusted hazard ratios (HR [95% confidence interval]) of HCC
for risk factors of interest. HIV-related factors included higher time-updated HIV RNA 
level, longer duration of detectable HIV (≥500 copies/mL), and lower time-updated 
CD4+ percentage. Traditional HCC risk factors examined included older age, black 
race, overweight/obesity, diabetes, alcohol dependence/abuse, ever use of tobacco, 
HBV coinfection, and HCV coinfection.16 Given the importance of cirrhosis on 
development of HCC, analyses were stratified by baseline cirrhosis status.
To evaluate the effects of HIV viremia on HCC risk, we created four separate 
models that examined HIV as a time-updated: 1) continuous variable by 1.0 log10 
increments (model #1), 2) categorical variable defined by detectable HIV (≥500 
copies/mL; model #2), 3) categorical variable classified by increasing categories of 
HIV RNA (<500 copies/mL; 500-9,999 copies/mL; ≥10,000 copies/mL; model #3), 
and 4) categorical variable classified by increasing consecutive months of 
detectable HIV (compared to those with undetectable HIV; model #4). For model 
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#4, detectable HIV was evaluated as a monthly time-updated variable. Once a 
patient was classified with HIV viremia, consecutive months were counted until a 
viral load <500 copies/mL was identified. If detectable HIV recurred, the count of 
consecutive months of viremia was restarted at one month. We determined HRs of 
HCC associated with increasing consecutive months of detectable HIV (1-11 months;
≥12 months) compared to persons whose HIV RNA was suppressed throughout 
follow-up, adjusting for all other risk factors.
We performed five sensitivity analyses to assess the robustness of our 
results. First, we repeated the analysis accounting for competing risk of death.27 
Second, we repeated analyses, lagging HIV RNA and CD4+ cell percentages by 360 
and 540 days. Third, we evaluated risk factors for HCC separately among persons 
with HBV coinfection, HCV coinfection, and without viral hepatitis. Fourth, to explore
the potential impact of hepatic steatosis on HCC risk, we classified patients with 
possible fatty liver disease prior to start of follow-up based on the presence of both 
obesity (BMI ≥30 kg/m2) and diabetes mellitus, since these act synergistically to 
promote steatosis,28 and examined associations with HCC. Fifth, since duration of 
HIV-related immunosuppression might affect HCC risk, we determined whether 
longer consecutive months with CD4+ percentage <14% increased risk of HCC. 
Finally, in an exploratory analysis, we examined the risk of HCC with lower time-
updated CD4+/CD8+ ratio, which indicates dysfunctional immune activation,29 by 
cirrhosis status.
Proportionality of hazards was assessed by log-log plots and Schoenfeld 
residuals.30 To address the potential bias of missing data among covariates, we 
implemented multiple imputation using chained equations by means of 10 
imputations using all variables in Table 1.31 Results across the 10 datasets were 
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combined to arrive at confidence intervals that accounted for within- and across-
dataset variances. Data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS 
Patient Characteristics
We identified 37,946 HIV-infected individuals in the VACS who had HIV RNA, 
CD4+, and CD8+ results measured simultaneously between October 1, 1999 and 
September 30, 2015. After exclusions, 35,659 remained in the final sample.
Patients in the cohort had a median age of 46 years at baseline and were 
predominantly male, black, and overweight/obese (Table 1). Tobacco use, alcohol 
dependence/abuse, and injection/non-injection drug use were common. At the start of 
follow-up, 56.7% had HIV RNA ≥500 copies/mL, 23.9% had CD4+ percentage <14%, 
and 88.5% had a CD4+/CD8+ ratio <1.0. A total of 31.9% had HCV coinfection, and 
5.6% were HBV-coinfected. Only 11.9% of HCV-coinfected persons received anti-HCV 
therapy at baseline or during follow-up.
Overall, 68.7% received ART during the baseline period. ART regimens 
prescribed reflected the antiretrovirals used at the time of study entry (Table 1). 
Among 1,981 HBV-coinfected individuals, 1,211 (61.1%) were on ART at baseline. Of 
these, 689 (56.9%) received HBV-active ART with lamivudine or emtricitabine alone, 
374 (30.9%) with tenofovir plus emtricitabine or lamivudine, and 27 (2.2%) with 
tenofovir alone; 121 (10.0%) were on ART without an HBV-active antiretroviral. By the
end of follow-up, 1,840 (92.9%) received HBV-active ART.
A total of 773 (2.2%) patients had a baseline diagnosis of cirrhosis. These 
patients were older and more commonly had diabetes, alcohol dependence/abuse, 
and HCV or HBV coinfection compared to those without cirrhosis (Table 1). 
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Incidence Rates of HCC
Overall, 302 medical record-confirmed HCC diagnoses were identified over 
281,441 person-years (IR, 107.3/100,000 person-years) with median duration of follow-
up of 7.4 (interquartile range, 3.3-12.8) years. Rates were particularly high among the 
1,981 HBV-coinfected (IR, 350.4/100,000 person-years) and 11,392 HCV-coinfected (IR, 
224.6/100,000 person-years) individuals. 
Patients diagnosed with HCC had a high prevalence of HCV coinfection 
(82.8%), alcohol dependence/abuse (63.2%), overweight/obesity (47.7%), and HBV 
coinfection (18.9%; Table 2). Notably, 99 (32.8%) did not have cirrhosis at HCC 
diagnosis (Table 2).
Determinants of HCC, by Baseline Cirrhosis Status
Among individuals without baseline cirrhosis, higher HIV RNA in model #1 
(1.25 [1.12-1.40] per 1.0 log10 copies/mL increase), detectable HIV in model #2 (1.46
[1.07-1.99]), HIV RNA ≥10,000 copies/mL in model #3 (1.63 [1.11-2.40]), and ≥12 
months of detectable HIV viremia in model #4 (1.47 [1.02-2.11]) increased the risk 
of HCC (Table 3). Absolute CD4+ counts <200 cells/mm3 increased HCC risk 
(Appendix 3); however, lower CD4+ percentage was not associated with an 
increased risk of HCC (Table 3). Additionally, in all models, older age, diabetes, HBV 
coinfection, HCV coinfection, history of alcohol dependence/abuse, and ever use of 
tobacco increased the risk of HCC (Table 3). Among individuals with baseline 
cirrhosis, only HBV and HCV coinfection were associated with HCC (Appendix 4). 
Results were similar in analyses accounting for the competing risk of death 
(data not shown) and using 360-day and 540-day lags for HIV RNA and CD4+ cell 
percentage (Appendix 5). Similar findings were observed when analyses were 
restricted to HBV-coinfected (Appendix 6) and HCV-coinfected (Appendix 7) 
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individuals, though results for some risk factors did not achieve statistical 
significance given the smaller sample sizes in these groups. There were too few HCC 
events (n=17) among HIV-infected patients without viral hepatitis to permit analysis.
When possible fatty liver disease was evaluated, patients who had both baseline 
obesity and diabetes had a higher risk of HCC than those who did not (2.32 [1.19-
4.52]; Appendix 8). Longer consecutive months with CD4+ percentage <14% did 
not increase HCC risk (≥12 months: 1.02 [0.69-1.51]; 1-11 months: 1.15 [0.65-2.05])
compared to those with ≥14% throughout follow-up. 
In exploratory analyses, after adjustment for HIV RNA and traditional risk 
factors, the risk of HCC was not increased with lower time-updated CD4+/CD8+ 
ratio among either individuals with baseline cirrhosis (1.000 [0.999-1.001] per 0.1 
unit decrease) or without cirrhosis (0.991 [0.981-1.002] per 0.1 unit decrease).
DISCUSSION
To our knowledge, this is the largest study to evaluate HIV-related and 
traditional risk factors for HCC among HIV-infected patients, and the first to 
examine such determinants by baseline cirrhosis status. We stratified our analyses 
by baseline cirrhosis status to account for the possibility that risk factors for HCC 
might vary by the presence of cirrhosis. Among patients without baseline cirrhosis, 
time-updated detectable HIV (≥500 copies/mL), higher HIV RNA (particularly 
≥10,000 copies/mL), and ≥12 months of detectable HIV increased risk of HCC, 
independent of traditional risk factors. Older age, HBV, HCV, diabetes, alcohol 
dependence/abuse, and tobacco use, which are traditional risk factors for HCC, also 
increased HCC risk in this group. The risk of HCC was particularly high in those with 
both obesity and diabetes. Among patients with baseline cirrhosis, only HBV and 
HCV coinfection remained associated with HCC. Notably, lower CD4+ cell 
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percentage was not associated with increased risk of HCC regardless of cirrhosis 
status.
Our study is the first to find that higher level and longer duration of HIV 
viremia contribute to HCC risk. HIV viremia could contribute to HCC by accelerating 
hepatic fibrosis progression to cirrhosis or by directly promoting 
hepatocarcinogenesis via immune dysregulation, oxidative stress, hepatocyte 
apoptosis, and/or depletion of CD4+ cells in the gastrointestinal tract with resultant 
microbial translocation.32-34 We have previously shown that suppression of HIV 
viremia can delay onset of cirrhosis.21 Our findings suggest that achieving and 
maintaining HIV suppression could mitigate the risk of HCC.
Three prior studies found no association between HIV RNA and risk of HCC, but
none stratified analyses by baseline cirrhosis status. One study of 31,576 HIV-
infected patients in the VA HIV Clinical Case Registry from 1985-2010 found that 
longer percentage of time with undetectable HIV RNA (<500 copies/mL) did not 
decrease HCC risk.5 A follow-up study among 8,563 HIV/HCV-coinfected patients in 
this registry similarly found no association between duration of undetectable HIV 
RNA and HCC.6 However, both analyses included cirrhosis as a covariate in 
multivariable models. Since cirrhosis is in the causal pathway to HCC, controlling for 
cirrhosis could have adjusted away associations between HIV suppression and HCC. 
A third study among 42,441 HIV-infected patients in the VACS from 1999-2015 found
that neither early (≤2 years) nor long-term (>2 years) HIV suppression decreased 
rates of HCC compared to 104,712 demographically similar uninfected persons.7 
However, this analysis did not stratify results by baseline cirrhosis status.
Contrary to previous studies,6,8-12 we found that HIV-related 
immunosuppression, as measured by CD4+ cell percentage, was not associated 
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with an increased risk of HCC. Notably, those prior studies evaluated the risk of HCC
associated with lower absolute CD4+ count. Indeed, when we evaluated 
associations between absolute CD4+ count and HCC in our cohort, CD4+ counts 
<200 cells/mm3 increased HCC risk. However, absolute CD4+ count may decrease 
during cirrhosis as a result of portal hypertension-induced splenic sequestration, but
CD4+ percentage remains unchanged during cirrhosis.13 Our results suggest that 
HIV-related immunosuppression is not an important contributor to HCC risk and that
the findings of prior analyses likely reflected the effect of liver fibrosis progression 
on absolute CD4+ count.
Interestingly, 32.8% of patients with HCC in our study did not have evidence 
of cirrhosis based on review of medical records within one year prior to cancer 
diagnosis. HCC can develop in the absence of advanced hepatic fibrosis in chronic 
HBV infection or non-alcoholic fatty liver disease.35,36 Further research is needed to 
determine how frequently HCC occurs in the absence of cirrhosis in HIV and if this 
differs from uninfected persons.
The study has several potential limitations. First, we might have 
underestimated cirrhosis, since this condition is clinically silent. However, cirrhosis 
was identified using validated diagnoses, and the negative predictive value of this 
definition exceeded 99%.23,24 Second, we were unable to determine fatty liver 
disease, since this diagnosis requires liver imaging or biopsy to confirm. We classified
possible fatty liver disease by baseline presence of both obesity and diabetes. Future 
studies should evaluate the effect of fatty liver disease on HCC in HIV. Third, we did 
not evaluate the risk of HCC with antiretroviral drugs, particularly those associated 
with hepatotoxicity,37 or viral hepatitis treatments. Additional research should 
evaluate the effects of these medications on incidence of HCC. Finally, our sample 
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was predominantly comprised of male US Veterans, but the study included 867 HIV-
infected women.
In conclusion, among HIV-infected patients without cirrhosis, higher HIV RNA 
and longer duration of HIV viremia, in addition to HBV and HCV coinfection, were 
important determinants of HCC, independent of traditional risk factors. HIV-related 
immunosuppression, determined by CD4+ cell percentage, was not associated with 
increased risk of HCC. This study provides the strongest evidence to date that HIV 
viremia contributes to the risk of HCC in this group.
17
345
346
347
348
349
350
351
352
FUNDING
This study was funded, in part, by the National Cancer Institute (R01CA206465) and
the National Institutes on Alcohol Abuse and Alcoholism (U01AA013566). 
NOTES
Affiliations of authors: Department of Medicine (JT, VLR), Department of 
Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and 
Biostatistics, Center for Pharmacoepidemiology Research and Training (MJK, DMC, 
VLR), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 
Center for Population Health Sciences, Stanford University School of Medicine, 
Stanford, CA (LSP); VA Connecticut Healthcare System, West Haven, CT (RLM, KD, 
JPT, JKL, THT, ACJ); Yale University School of Medicine, New Haven, CT (RLM, KD, JPT,
JKL, THT, ACJ); VA Greater Los Angeles Healthcare System and David Geffen School 
of Medicine at UCLA, Los Angeles, CA (MBG); Infectious Diseases Section, Michael E. 
DeBakey VA Medical Center and Department of Medicine, Baylor College of 
Medicine, Houston, TX (MCR); Washington DC VA Medical Center and George 
Washington University Medical Center, Washington, DC (CLG); James J. Peters VA 
Medical Center, Bronx, NY and Icahn School of Medicine at Mount Sinai, New York, 
NY (NB); Department of Biostatistics, Rutgers University School of Public Health, 
New Brunswick, NJ (JAR).
The funding agencies had no involvement in the design of the study; the 
collection of data, analysis or interpretation of results; the development of this 
manuscript; or the decision to submit the manuscript for publication.
The authors have no conflicts of interest to disclose.  
The views expressed in this article are those of the authors and do not 
necessarily reflect the position or policy of the Department of Veterans Affairs or the 
18
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
United States Government.
19
379
REFERENCES
1. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among 
people with treated human immunodeficiency virus infection in North America. Clin 
Infect Dis 2017; 65(4): 636-43.
2. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative Incidence of Cancer 
Among Persons With HIV in North America: A Cohort Study. Ann Intern Med 2015; 
163(7): 507-18.
3. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of 
hepatocellular carcinoma among individuals with acquired immunodeficiency 
syndrome in the United States. Cancer 2012; 118(24): 6226-33.
4. Pinato DJ, Allara E, Chen TY, et al. Influence of HIV Infection on the Natural 
History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin 
Oncol 2019; 37(4): 296-304.
5. Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY. Cumulative HIV viremia 
and non-AIDS-defining malignancies among a sample of HIV-infected male veterans.
J Acquir Immune Defic Syndr 2014; 67(2): 204-11.
6. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control 
on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV 
coinfection. J Acquir Immune Defic Syndr 2015; 68(4): 456-62.
7. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower 
AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected Veterans: A 
prospective cohort study. Ann Intern Med 2018; 169(2): 87-96.
8. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related 
immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22(16): 
2135-41.
20
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
9. Bruyand M, Dabis F, Vandenhende MA, et al. HIV-induced immune deficiency 
is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, 
France, 1998-2008. J Hepatol 2011; 55(5): 1058-62.
10. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence
of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency 
virus infection. Hepatology 2013; 57(1): 249-57.
11. Merchante N, Merino E, Lopez-Aldeguer J, et al. Increasing incidence of 
hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 
56(1): 143-50.
12. Gjaerde LI, Shepherd L, Jablonowska E, et al. Trends in incidences and risk 
factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C 
virus-coinfected individuals from 2001 to 2014: A multicohort study. Clin Infect Dis 
2016; 63(6): 821-9.
13. McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell 
counts in HIV-seronegative patients. Clin Infect Dis 2007; 44(3): 431-7.
14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 
379(9822): 1245-55.
15. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology 2007; 132(7): 2557-76.
16. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the 
United States: where are we? Where do we go? Hepatology 2014; 60(5): 1767-75.
17. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a 
"virtual" cohort using the National VA Health Information System. Med Care 2006; 
44(8 Suppl 2): S25-30.
21
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
18. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al, eds. 
International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health 
Organization; 2000.
19. National Cancer Institute. Surveillance, Epidemiology, and End Results 
Program: Site Recode ICD-O-3/WHO 2008 Definition. Accessed at 
http://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html on 16 August 2018.
20. Park LS, Tate JP, Rodriguez-Barradas MC, et al. Cancer Incidence in HIV-
Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 
Code Diagnoses. Journal of AIDS & clinical research 2014; 5(7): 1000318.
21. Lo Re V, 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in 
antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared 
with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 
160(6): 369-79.
22. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk 
of diabetes mellitus. AIDS 2009; 23(10): 1227-34.
23. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The 
validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs 
administrative databases. Aliment Pharmacol Ther 2008; 27(3): 274-82.
24. Lo Re V, 3rd, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-
related laboratory abnormalities to identify hepatic decompensation events in the 
Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20(7): 689-99.
25. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive 
index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 
2006; 43(6): 1317-25.
22
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
26. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated 
hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of
tumor growth rate and patient survival. Hepatology 1992; 16(1): 132-7.
27. Fine J, Gray RJ. A proportional hazards model for the subdistribution of 
competing risk. J Am Stat Assoc 1999; 94: 496-509.
28. Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, 
diagnosis, cardiometabolic consequences, and treatment strategies. Lancet 
Diabetes Endocrinol 2019; 7(4): 313-24.
29. Serrano-Villar S, Gutierrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-
infected subjects is independently associated with T-cell activation despite long-
term viral suppression. J Infect 2013; 66(1): 57-66.
30. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of 
Time-to-Event Data. New York, NY: John Wiley & Sons, Inc.; 1999.
31. Royston P. Multiple imputation of missing values: update. The STATA Journal 
2005; 5(2): 188-201.
32. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-
related microbial translocation and progression of hepatitis C. Gastroenterology 
2008; 135(1): 226-33.
33. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, 
and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin 
Infect Dis 2012; 55(1): 126-36.
34. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/
HCV-coinfected patients with successful HIV suppression using antiretroviral 
therapy. J Hepatol 2006; 44(1): 47-55.
23
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
35. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence
of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver 
disease. Clin Gastroenterol Hepatol 2016; 14(1): 124-31 e1.
36. Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the 
absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 
2017; 66(2): 355-62.
37. Ryom L, Lundgren JD, De Wit S, et al. Use of antiretroviral therapy and risk of 
end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS 
2016; 30(11): 1731-43.
24
477
478
479
480
481
482
483
484
485
486
Figure 1. Pathway to development of hepatocellular carcinoma (HCC). The figure shows the 
contributions of the key modifiable determinants of HCC, including traditional risk factors 
(blue) and the hypothesized HIV-related determinants in this study (red). Both chronic 
hepatitis B virus (HBV) infection and HIV viremia could increase the risk of HCC by inducing 
hepatic fibrosis and cirrhosis or by directly promoting development of HCC outside of the liver 
fibrosis pathway.
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Table 1. Baseline characteristics of study patients, stratified by cirrhosis diagnosis.
Characteristic* Overall(n=35,659)
Baseline
No Cirrhosis†
(n=34,886)
Baseline
Cirrhosis†
(n=773)
Median age (years, IQR) 46 (39-53) 46 (39-53) 49 (44-55)
Male sex 34,792 (97.6) 34,032 (97.6) 760 (98.3)
Race/ethnicity
Black 17,069 (47.9) 16,750 (48.0) 319 (41.3)
Caucasian 13,859 (38.9) 13,522 (38.8) 337 (43.6)
Hispanic 2,720 (7.6) 2,632 (7.5) 88 (11.4)
Other/Unknown 2,011 (5.6) 1,982 (5.7) 29 (3.8)
Body mass index
Underweight (<18.50 kg/m2) 837 (2.3) 819 (2.3) 18 (2.3)
Normal (18.50-24.99 kg/m2) 14,083 (39.5) 13,768 (39.5) 315 (40.8)
Overweight (25.00-29.99 kg/m2) 11,415 (32.0) 11,184 (32.1) 231 (29.9)
Obesity (30.00-34.99 kg/m2) 3,882 (10.9) 3,789 (10.9) 93 (12.0)
Morbid obesity (35.00 kg/m2) 1,323 (3.7) 1,299 (3.7) 24 (3.1)
Missing weight and/or height 4,119 (11.6) 4,027 (11.5) 92 (11.9)
Diabetes mellitus 3,308 (9.3) 3,150 (9.0) 158 (20.4)
History of alcohol dependence/abuse 10,538 (29.6) 10,064 (28.8) 474 (61.3)
History of injection/non-injection drug 
use
16,235 (45.5) 15,781 (45.2) 454 (58.7)
Tobacco use
Never 9,533 (26.7) 9,393 (26.9) 140 (18.1)
Ever‡ 24,707 (69.3) 24,158 (69.2) 549 (71.0)
Unknown 1,419 (4.0) 1,335 (3.8) 84 (10.9)
Hepatitis C virus coinfection§
Detectable HCV RNA or genotype 11,392 (31.9) 10,940 (31.4) 452 (58.5)
Ever treated with HCV antiviral 1,354 (11.9) 1,304 (11.9) 50 (11.1)
HCV antibody+/HCV RNA- 1,055 (3.0) 1,020 (2.9) 35 (4.5)
HCV antibody- 21,472 (60.2) 21,247 (60.9) 225 (29.1)
Never tested 1,740 (4.9) 1,679 (4.8) 61 (7.9)
Hepatitis B virus coinfection||
HBsAg+ 1,981 (5.6) 1,873 (5.4) 108 (14.0)
Ever treated with HBV-active 
antiretroviral
1,840 (92.9) 1,748 (93.3)  92 (85.2)
HBsAg- 31,712 (88.9) 31,096 (89.1) 616 (79.7)
Never tested 1,966 (5.5) 1,917 (5.5) 49 (6.3)
HIV RNA
Median (log10 cells/mm3, IQR) 3.2 (1.7-4.6) 3.2 (1.7-4.6) 3.0 (1.7-4.6)
500 copies/mL 20,216 (56.7) 19,791 (56.7) 425 (55.0)
CD4+ cell percentage
Median (%, IQR) 22 (14-31) 22 (14-31) 22 (14-31)
≥28% 11,776 (33.0) 11,530 (33.1) 246 (31.8)
14-27.99% 14,798 (41.5) 14,456 (41.4) 342 (44.2)
<14%
Unknown
8,513 (23.9)
572 (1.6)
8,337 (23.9)
563 (1.6)
176 (22.8)
9 (1.2)
CD4+/CD8+ ratio
Median (IQR) 0.40 (0.21-0.69) 0.40 (0.21-0.69) 0.42 (0.21-
0.70)
<1.0 31,553 (88.5) 30,879 (88.5) 674 (87.2)
Median alanine aminotransferase (U/L) 31 (21-47) 30 (21-47) 41 (27-71)
Not assessed at baseline 2,362 (6.6) 2,338 (6.7) 24 (3.1)
Median aspartate aminotransferase 
(U/L)
30 (23-44) 29 (22-43) 55 (32-94)
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Characteristic* Overall(n=35,659)
Baseline
No Cirrhosis†
(n=34,886)
Baseline
Cirrhosis†
(n=773)
Not assessed at baseline 1,987 (5.6) 1,964 (5.6) 23 (3.0)
Platelet count (x 106/L)
150,000 30,570 (85.7) 30,194 (86.6) 376 (48.6)
<150,000 4,812 (13.5) 4,420 (12.7) 392 (50.7)
Not assessed at baseline 277 (0.8) 272 (0.8) 5 (0.6)
Median baseline FIB-4 (IQR) 1.18 (0.81-1.78) 1.17 (0.81-1.74) 3.00 (1.58-
5.82)
Unable to be calculated at baseline 3,325 (9.3) 3,290 (9.4) 35 (4.5)
On antiretroviral therapy 24,506 (68.7) 23,980 (68.7) 526 (68.0)
Most common baseline antiretroviral 
regimens¶
Efavirenz/tenofovir/emtricitabine 3,639 (14.8) 3,565 (14.9) 74 (14.1)
Efavirenz/zidovudine/lamivudine 1,764 (7.2) 1,738 (7.2) 26 (4.9)
Nelfinavir/zidovudine/lamivudine 1,177 (4.8) 1,156 (4.8) 21 (4.0)
Indinavir/zidovudine/lamivudine
Atazanavir/tenofovir/emtricitabine 
1,033 (4.2)
965 (3.9)
1,015 (4.2)
950 (4.0)
18 (3.4)
15 (2.9)
Nelfinavir/stavudine/lamivudine 888 (3.6) 863 (3.6) 25 (4.8)
Indinavir/stavudine/lamivudine 725 (3.0) 708 (3.0) 17 (3.2)
Nevirapine/zidovudine/lamivudine 663 (2.7) 652 (2.7) 11 (2.1)
Efavirenz/stavudine/lamivudine 611 (2.5) 590 (2.5) 21 (4.0)
Abbreviations: HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IQR=interquartile range; RNA=ribonucleic acid
* Results reported as n (%) unless otherwise specified.
† Cirrhosis defined as any diagnosis of compensated or decompensated cirrhosis prior to the start of follow-
up.
‡ Ever tobacco use includes current and prior tobacco use.
§ Hepatitis C virus coinfection defined as positive quantitative HCV RNA (absolute value determinable or 
not), positive qualitative HCV RNA, or quantifiable HCV genotype at baseline or during follow-up.
|| Hepatitis B virus coinfection defined as positive HBV surface antigen at baseline or during follow-up.
¶ Percentages represent proportion of antiretroviral use among patients prescribed therapy.
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Table 2. Characteristics of patients with incident hepatocellular carcinoma, stratified by 
cirrhosis as determined by review of medical records within one year prior to diagnosis.
Characteristic*
Overall 
Incident HCC 
(n=302)
No Evidence of
Cirrhosis
(n=99)
Evidence of
Cirrhosis
(n=203)
Median age at diagnosis (years, IQR) 56.4 (51.3-61.1) 57.5 (51.3-61.8) 56.0 (51.3-60.9)
Median time to diagnosis (years, IQR) 7.2 (3.9-10.6) 6.3 (3.5-10.3) 7.4 (4.2-11.1)
Male sex 299 (99.0) 99 (100.0) 200 (98.5)
Race/ethnicity
Black 159 (52.6) 62 (62.6) 97 (47.8)
Caucasian 97 (32.1) 24 (24.2) 73 (36.0)
Hispanic 37 (12.3) 10 (10.1) 27 (13.3)
Other/Unknown 9 (3.0) 3 (3.0) 6 (3.0)
Body mass index
Underweight (<18.50 kg/m2) 25 (8.3) 16 (16.2) 9 (4.4)
Normal (18.50-24.99 kg/m2) 128 (42.4) 47 (47.5) 81 (39.9)
Overweight (25.00-29.99 kg/m2) 102 (33.8) 25 (25.3) 77 (37.9)
Obesity (30.00-34.99 kg/m2) 34 (11.3) 9 (9.1) 25 (12.3)
Morbid obesity (35.00 kg/m2)
Missing weight and/or height
8 (2.6)
5 (1.7)
2 (2.0)
0 (0.0)
6 (3.0)
5 (2.5)
Diabetes mellitus 94 (31.1) 24 (24.2) 70 (34.5)
History of alcohol dependence/abuse 191 (63.2) 61 (61.6) 130 (64.0)
History of injection/non-injection drug use 246 (81.5) 81 (81.8) 165 (81.3)
Tobacco use
    Never 40 (13.2) 10 (10.1) 30 (14.8)
    Ever† 262 (86.8) 89 (89.9) 173 (85.2)
Hepatitis C virus coinfection‡
Detectable HCV RNA or genotype 250 (82.8) 79 (79.8) 171 (84.2)
HCV antibody+/HCV RNA- 5 (1.7) 1 (1.0) 4 (2.0)
HCV antibody- 39 (12.9) 15 (15.2) 24 (11.8)
Never tested 8 (2.6) 4 (4.0) 4 (2.0)
Hepatitis B virus coinfection§
    HBsAg+ 57 (18.9) 17 (17.2) 40 (19.7)
HBsAg- 236 (78.1) 79 (79.8) 157 (77.3)
Never tested 9 (3.0) 3 (3.0) 6 (3.0)
Median HIV RNA (log10 copies/mL, IQR) 1.7 (1.7-2.6) 1.7 (1.7-2.6) 1.7 (1.7-2.7)
CD4 percentage
Median (%, IQR) 26 (17-35) 26 (14-35) 26 (18-35)
≥28% 135 (44.7) 42 (42.4) 93 (45.8)
14-27.99% 120 (39.7) 35 (35.4) 85 (41.9)
<14%  47 (15.6) 22 (22.2) 25 (12.3)
CD4:CD8 ratio
Median (IQR) 0.57 (0.31-0.93) 0.52 (0.26-0.98) 0.59 (0.33-0.91)
<1.0 239 (79.1) 77 (77.8) 162 (79.8)
Median alanine aminotransferase (U/L, IQR) 54 (36-79) 52 (35-74) 57 (36-79)
Not assessed within 360 days prior to HCC 
diagnosis
2 (0.7) 0 (0.0) 2 (1.0)
Median aspartate aminotransferase (U/L, 
IQR)
68 (44-101) 61 (38-95) 73 (47-104)
Not assessed within 360 days prior to HCC 
diagnosis
1 (0.3) 0 (0.0) 1 (0.5)
Platelet count <150,000 x 106/L 172 (57.0) 42 (42.4) 130 (64.0)
28
506
507
Characteristic*
Overall 
Incident HCC 
(n=302)
No Evidence of
Cirrhosis
(n=99)
Evidence of
Cirrhosis
(n=203)
FIB-4||
    <1.45
    1.45-3.25
    >3.25
    Insufficient data to calculate FIB-4
27 (8.9)
99 (32.8)
173 (57.3)
3 (1.0)
18 (18.2)
39 (39.4)
42 (42.4)
0 (0.0)
9 (4.4)
60 (29.6)
131 (64.5)
3 (1.5)
On antiretroviral therapy 229 (75.8) 77 (77.8) 152 (74.9)
Ever dideoxynucleoside analogue use¶ 207 (68.5) 74 (74.7) 133 (65.5)
Abbreviations: HBsAg=hepatitis B surface antigen; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IQR=interquartile range; NRTI=nucleoside reverse transcriptase 
inhibitors; RNA=ribonucleic acid
* Results reported as n (%) unless otherwise specified.
† Ever tobacco use includes current and prior tobacco use.
‡ Hepatitis C virus coinfection defined as positive quantitative HCV RNA (absolute value determinable or not), 
positive qualitative HCV RNA, or quantifiable HCV genotype at baseline or during follow-up.
§ Hepatitis B virus coinfection defined as positive HBV surface antigen at baseline or during follow-up.
|| FIB-4 was calculated using current age and most recent alanine aminotransferase, aspartate 
aminotransferase, and platelet count within 360 days prior to HCC diagnosis.
¶ Included didanosine, stavudine, zalcitabine, and zidovudine.   
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Table 3. Factors associated with incident hepatocellular carcinoma among HIV-infected patients in the Veterans 
Aging Cohort Study (October 1, 1999-September 30, 2015) without a baseline diagnosis of cirrhosis (n=34,886; 270 
hepatocellular carcinoma events).
Characteristic Unadjusted HR(95% CI)
Model #1*
Adj. HR
(95% CI)
Model #2†
Adj. HR
(95% CI)
Model #3‡
Adj. HR
(95% CI)
Model #4§
Adj. HR
(95% CI)
Age (per 10 years) 1.33 (1.17-1.51) 1.48 (1.26-1.73)
1.44 (1.23-
1.69)
1.45 (1.23-
1.70)
1.44 (1.23-
1.69)
Male sex 2.30 (0.74-7.19) 1.38 (0.44-4.31)
1.37 (0.44-
4.30) 1.37 (0.44-4.29)
1.37 (0.44-
4.30)
Race
White Reference Reference Reference Reference Reference
Black 1.50 (1.15-1.97) 0.97 (0.73-1.28)
0.97 (0.74-
1.29) 0.97 (0.74-1.29)
0.97 (0.74-
1.29)
Hispanic 1.77 (1.17-2.68) 1.24 (0.82-1.89)
1.23 (0.81-
1.87) 1.23 (0.81-1.88)
1.23 (0.81-
1.87)
Other 1.40 (0.68-2.89) 1.72 (0.83-3.58)
1.72 (0.83-
3.56) 1.71 (0.83-3.55)
1.72 (0.83-
3.56)
Baseline body mass index
Underweight (<18.50 kg/m2) 0.63 (0.18-2.15) 0.59 (0.17-
2.08)
0.59 (0.17-
2.09) 0.59 (0.17-2.09)
0.59 (0.17-
2.09)
Normal (18.50-24.99 kg/m2) Reference Reference Reference Reference Reference
Overweight (25.00-29.9 kg/m2) 0.88 (0.67-1.17) 0.96 (0.72-
1.27)
0.96 (0.72-
1.27) 0.96 (0.72-1.27)
0.96 (0.72-
1.27)
Obesity (30.00-34.9 kg/m2) 0.92 (0.61-1.40) 1.01 (0.65-
1.56)
1.01 (0.65-
1.56)
1.01 (0.65-1.56) 1.01 (0.65-
1.56)
Morbid obesity (35.00 kg/m2) 0.84 (0.39-1.80) 0.98 (0.45-
2.14)
0.98 (0.45-
2.13) 0.98 (0.45-2.13)
0.98 (0.45-
2.13)
Time-updated diabetes mellitus
Hepatitis B virus coinfection
   HBsAg-
   HBsAg+
   Never tested
1.70 (1.32-2.20)
Reference
3.65 (2.68-4.97)
1.01 (0.48-2.15)
1.46 (1.12-
1.91)
Reference
3.92 (2.87-
5.35)
1.12 (0.52-
2.42)
1.45 (1.11-
1.90)
Reference
3.91 (2.86-
5.34)
1.13 (0.52-
2.44)
1.45 (1.11-
1.90)
Reference
3.91 (2.86-
5.35)
1.13 (0.52-2.44)
1.45 (1.11-
1.90)
Reference
3.91 (2.86-
5.34)
1.13 (0.52-
2.44)
Hepatitis C virus coinfection
HCV antibody- Reference Reference Reference Reference Reference
Detectable HCV RNA or genotype 9.25 (6.53-13.11)
7.65 (5.35-
10.94)
7.68 (5.36-
10.98)
7.68 (5.37-
11.00)
7.68 (5.36-
10.98)
HCV antibody+/HCV RNA- 4.83 (1.90-12.28)
3.73 (1.46-
9.52)
3.81 (1.49-
9.72)
3.80 (1.49-
9.71)
3.81 (1.49-
9.72)
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Characteristic Unadjusted HR(95% CI)
Model #1*
Adj. HR
(95% CI)
Model #2†
Adj. HR
(95% CI)
Model #3‡
Adj. HR
(95% CI)
Model #4§
Adj. HR
(95% CI)
Never tested 4.85 (2.16-10.88)
4.64 (2.04-
10.55)
4.68 (2.06-
10.65)
4.68 (2.06-
10.64)
4.68 (2.06-
10.65)
Time-updated CD4+ cell percentage
≥28%
14%-27.99%
<14%
Reference
1.05 (0.81-1.37)
1.52 (1.08-2.14)
Reference
0.86 (0.66-
1.12)
0.97 (0.66-
1.43)
Reference
0.89 (0.68-
1.16)
1.12 (0.78-
1.62)
Reference
0.88 (0.68-1.16)
1.09 (0.75-1.59)
Reference
0.89 (0.68-
1.16)
1.12 (0.78-
1.62)
History of alcohol abuse 2.38 (1.85-3.05) 1.45 (1.11-1.89)
1.46 (1.12-
1.90)
1.46 (1.12-
1.90)
1.46 (1.12-
1.90)
Tobacco use
    Never Reference Reference Reference Reference Reference
Ever|| 2.58 (1.81-3.67) 1.65 (1.14-2.38)
1.66 (1.15-
2.39)
1.66 (1.15-
2.40)
1.66 (1.15-
2.39)
Time-updated HIV RNA (per 1.0 log10
copies/mL)
1.26 (1.14-1.39) 1.25 (1.12-
1.40)
- - -
Current HIV RNA ≥500 copies/mL
Current HIV RNA categories
<500 copies/mL
500-9,999 copies/mL
10,000+ copies/mL
Consecutive months of HIV RNA 
≥500 copies/mL
1.58 (1.19-2.10)
Reference
1.41 (0.94-2.11)
1.73 (1.22-2.47)
-
-
-
1.46 (1.07-
1.99)
-
-
-
Reference
1.31 (0.87-
1.97)¶
1.63 (1.11-
2.40)¶
-
-
HIV RNA always <500 copies/mL Reference - - Reference
1-11 months of HIV RNA ≥500 copies/
mL
1.63 (1.07-2.49) - - 1.46 (0.94-
2.26)
≥12 months of HIV RNA ≥500 
copies/mL
1.55 (1.10-2.18) - - 1.47 (1.02-
2.11)
Abbreviations: CI=confidence interval; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; HR=hazard ratio; RNA=ribonucleic acid
* Model #1 includes continuous values of HIV RNA as log10 copies/mL
† Model #2 includes current HIV RNA ≥500 copies/mL
‡ Model #3 includes current categories of HIV RNA ≥500 copies/mL
§ Model #4 includes consecutive months of HIV RNA ≥500 copies/mL
|| Ever tobacco use includes current and prior tobacco use
¶ p for trend=0.01.
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